Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of DME for…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic macular edema (DME) patient populations covering 171…
Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…
Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…
Clarivate Epidemiology’s coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of benign…
Clarivate Epidemiology’s coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of benign…
Clarivate Epidemiology’s coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of benign…
Clarivate Epidemiology’s coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of benign…
Clarivate Epidemiology’s coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of benign…
Clarivate Epidemiology’s coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of benign…
Clarivate Epidemiology’s coverage of BPH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of BPH for each country, as well as…
Clarivate Epidemiology’s coverage of male hypogonadism comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key BPH patient populations covering 171 countries and more than 99% of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…